3056 related articles for article (PubMed ID: 28104981)
1. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.
Zhou D; Pan Q; Xin FZ; Zhang RN; He CX; Chen GY; Liu C; Chen YW; Fan JG
World J Gastroenterol; 2017 Jan; 23(1):60-75. PubMed ID: 28104981
[TBL] [Abstract][Full Text] [Related]
2. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota.
Zhou D; Pan Q; Shen F; Cao HX; Ding WJ; Chen YW; Fan JG
Sci Rep; 2017 May; 7(1):1529. PubMed ID: 28484247
[TBL] [Abstract][Full Text] [Related]
3. Supplementation with Sodium Butyrate Modulates the Composition of the Gut Microbiota and Ameliorates High-Fat Diet-Induced Obesity in Mice.
Fang W; Xue H; Chen X; Chen K; Ling W
J Nutr; 2019 May; 149(5):747-754. PubMed ID: 31004166
[TBL] [Abstract][Full Text] [Related]
4. SIRT3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis.
Chen M; Hui S; Lang H; Zhou M; Zhang Y; Kang C; Zeng X; Zhang Q; Yi L; Mi M
Mol Nutr Food Res; 2019 Feb; 63(4):e1800612. PubMed ID: 30525304
[TBL] [Abstract][Full Text] [Related]
5. The combination of Ilexhainanoside D and ilexsaponin A
Zhao W; Xiao M; Yang J; Zhang L; Ba Y; Xu R; Liu Z; Zou H; Yu P; Wu X; Chen X
Phytomedicine; 2019 Oct; 63():153039. PubMed ID: 31387054
[TBL] [Abstract][Full Text] [Related]
6. Hepatobiliary and pancreatic: Multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota.
Shou D; Luo Q; Tang W; Cao C; Huang H; Chen H; Zhou Y
J Gastroenterol Hepatol; 2023 Dec; 38(12):2195-2205. PubMed ID: 37787118
[TBL] [Abstract][Full Text] [Related]
7. Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis
Liu MT; Huang YJ; Zhang TY; Tan LB; Lu XF; Qin J
World J Gastroenterol; 2019 Jul; 25(27):3590-3606. PubMed ID: 31367159
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
9. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats.
Shen SH; Zhong TY; Peng C; Fang J; Lv B
BMC Complement Med Ther; 2020 Feb; 20(1):34. PubMed ID: 32024509
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.
Cao Y; Pan Q; Cai W; Shen F; Chen GY; Xu LM; Fan JG
Arch Iran Med; 2016 Mar; 19(3):197-203. PubMed ID: 26923892
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis.
Chiu CC; Ching YH; Li YP; Liu JY; Huang YT; Huang YW; Yang SS; Huang WC; Chuang HL
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29113135
[TBL] [Abstract][Full Text] [Related]
12. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
[TBL] [Abstract][Full Text] [Related]
13. Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis.
Vitaglione P; Mazzone G; Lembo V; D'Argenio G; Rossi A; Guido M; Savoia M; Salomone F; Mennella I; De Filippis F; Ercolini D; Caporaso N; Morisco F
J Nutr Sci; 2019; 8():e15. PubMed ID: 31037218
[TBL] [Abstract][Full Text] [Related]
14. Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression.
Zhang N; Qu Y; Qin B
Clin Exp Pharmacol Physiol; 2021 Aug; 48(8):1125-1136. PubMed ID: 33721354
[TBL] [Abstract][Full Text] [Related]
15. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats.
Zhong M; Yan Y; Yuan H; A R; Xu G; Cai F; Yang Y; Wang Y; Zhang W
Food Funct; 2022 Jul; 13(13):7287-7301. PubMed ID: 35726797
[TBL] [Abstract][Full Text] [Related]
16. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
Wang P; Wang J; Li D; Ke W; Chen F; Hu X
J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
[TBL] [Abstract][Full Text] [Related]
17. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
18. Butyrate ameliorates chronic alcoholic central nervous damage by suppressing microglia-mediated neuroinflammation and modulating the microbiome-gut-brain axis.
Wei H; Yu C; Zhang C; Ren Y; Guo L; Wang T; Chen F; Li Y; Zhang X; Wang H; Liu J
Biomed Pharmacother; 2023 Apr; 160():114308. PubMed ID: 36709599
[TBL] [Abstract][Full Text] [Related]
19. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
Wang W; Zhao J; Gui W; Sun D; Dai H; Xiao L; Chu H; Du F; Zhu Q; Schnabl B; Huang K; Yang L; Hou X
Br J Pharmacol; 2018 Feb; 175(3):469-484. PubMed ID: 29139555
[TBL] [Abstract][Full Text] [Related]
20. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
